The immunoRIV project was designed by the INSERM team (coordinating institution) headed by Dr Jean-Pierre Pouget, to better understand the immune system role in the clinical efficacy of targeted radionuclide therapy (TRT; radiothérapie interne vectorisée, RIV, in French). The aim is to analyse and characterize immune cells in tumours and in blood to predict the response to treatment.
This translational cancer research project was selected by the French National Cancer Institute (INCa) (PRT-K 2021-2022) and is under the scientific responsibility of Dr Julie Constanzo and the clinical responsibility of Dr Emmanuel Deshayes (TEAM 2). It has received support from INCa and the Direction Générale de l’Offre de Soins (DGOS; French general directorate for the healthcare offer) for a total amount of 502,606 euros.

It is carried out in close collaboration with the teams of Dr Florent Ginhoux (UMR 1095, Gustave Roussy | TEAM 3), Dr Evelyne Crapez (Translational Research Unit, ICM | TEAM 4), and the ICM Department of Clinical Research and Innovation. To address the study objective, 70 patients with neuroendocrine tumours and 70 patients with metastatic thyroid cancer must be included at three centres in France: ICM, Institut Universitaire de Cancérologie of Toulouse (Prof Frédéric Courbon‘s team | TEAM 5), and Hôpital Haut Lévêque of Bordeaux (Prof Elif Hindié‘s team | TEAM 6).

The BCB RIV, a biobank coordinated by Dr Deshayes, is at the origin of this ancillary project. The BCB RIV biobank, supervised by SIRIC2 Montpellier, has been open for inclusion since 2019 and its objective is to develop a prospective clinical-biological database dedicated to patients with prostate, thyroid and neuroendocrine tumours treated with TRT.